|Dr. Rene Russo BCPS, Pharm.D||Co-Founder & Independent Chair of the Board||78.34k||N/A||1975|
|Dr. Tillman Ulf Gerngross Ph.D.||Co-Founder, CEO, Pres & Director||N/A||N/A||1964|
|Dr. Rebecca Dabora Ph.D.||Chief Technology & Manufacturing Officer||622.28k||N/A||1959|
|Ms. Lynn Connolly M.D., Ph.D.||Chief Medical Officer||430.89k||N/A||1967|
|Ms. Laura Walker Ph.D.||Co-Founder & Chief Scientific Officer||N/A||N/A||1985|
|Ms. Jane Pritchett V. Henderson||CFO & Treasurer||N/A||N/A||1966|
|Mr. David Hering M.B.A.||Chief Operating Officer||N/A||N/A||1975|
|Ms. Jill Andersen J.D.||Chief Legal Officer||N/A||N/A||N/A|
|Dr. Elham Hershberger Pharm.D.||Chief Devel. Officer||N/A||N/A||1968|
|Mr. Eric W. Kimble M.B.A.||Chief Commercial Officer||N/A||N/A||1967|
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. Its lead product candidate is the ADG20, a neutralizing antibody that is in Phase II/III clinical trials for the treatment and prevention of coronavirus disease. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. Adagio Therapeutics, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts.
Adagio Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.